Loading…
Loading…
KLYG does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KLYG and 80,000+ other tickers.
See exactly how KLYG's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KLYG and 80,000+ other tickers.
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-grade polymers. Additionally, Kelyniam develops, produces, and supplies specific cranial and craniofacial fixation screws, crucial for the reconstruction of skull and facial structures. Its clientele encompasses health systems, hospitals, sales representatives, surgeons, insurance providers (payors), and individual patients. Established in 2005, the…
CANTON, CT / ACCESS Newswire / August 11, 2026 / Kelyniam Global (OTCID:KLYG), a leader in custom cranial implants, today reported its financial results for the six months ended June 30, 2026. The company delivered excellent performance, with strong revenue growth and a clear improvement in profitability.
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader PR Newswire
COLLINSVILLE, Conn., June 1, 2026 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leader in patient-specific cranial and craniofacial implants, today announced it will present at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 4:30 PM PST at the Bellagio Resort & Hotel.
CANTON, Conn., May 11, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today reported its financial results for the first quarter ended March 31, 2026.
Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusion™ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today announced its financial results for the year ended December 31, 2025.